<?xml version="1.0" encoding="UTF-8"?>
<p>At present, clinical trials have been conducted in China to evaluate its effect on the treatment of COVID-19. On February 4, 2020, Li Lanjuan's team released the latest research results in Wuhan: Abidol and Darunavir can effectively inhibit SARS-COV-2, which is a significant finding in treating COVID-19. To date, most of the broad-spectrum antiviral drugs used in clinical practice, and the therapeutic effect mostly needs practical evaluation. Blind use of antibacterial drugs should be avoided, especially in combination with broad-spectrum antibacterial drugs.
 <sup>[
  <xref rid="R39" ref-type="bibr">39</xref>]
 </sup>
</p>
